111 related articles for article (PubMed ID: 21538421)
1. TP53INP1 overexpression in prostate cancer correlates with poor prognostic factors and is predictive of biological cancer relapse.
Giusiano S; Garcia S; Andrieu C; Dusetti NJ; Bastide C; Gleave M; Taranger-Charpin C; Iovanna JL; Rocchi P
Prostate; 2012 Feb; 72(2):117-28. PubMed ID: 21538421
[TBL] [Abstract][Full Text] [Related]
2. TP53INP1 as new therapeutic target in castration-resistant prostate cancer.
Giusiano S; Baylot V; Andrieu C; Fazli L; Gleave M; Iovanna JL; Taranger-Charpin C; Garcia S; Rocchi P
Prostate; 2012 Sep; 72(12):1286-94. PubMed ID: 22213058
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
[TBL] [Abstract][Full Text] [Related]
4. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer.
Fritzsche FR; Jung M; Tölle A; Wild P; Hartmann A; Wassermann K; Rabien A; Lein M; Dietel M; Pilarsky C; Calvano D; Grützmann R; Jung K; Kristiansen G
Eur Urol; 2008 Nov; 54(5):1097-106. PubMed ID: 18061337
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of Fn14 promotes androgen-independent prostate cancer progression through MMP-9 and correlates with poor treatment outcome.
Huang M; Narita S; Tsuchiya N; Ma Z; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Habuchi T
Carcinogenesis; 2011 Nov; 32(11):1589-96. PubMed ID: 21828059
[TBL] [Abstract][Full Text] [Related]
6. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.
Rocchi P; Boudouresque F; Zamora AJ; Muracciole X; Lechevallier E; Martin PM; Ouafik L
Cancer Res; 2001 Feb; 61(3):1196-206. PubMed ID: 11221851
[TBL] [Abstract][Full Text] [Related]
7. GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Narita S; So A; Ettinger S; Hayashi N; Muramaki M; Fazli L; Kim Y; Gleave ME
Clin Cancer Res; 2008 Sep; 14(18):5769-77. PubMed ID: 18794086
[TBL] [Abstract][Full Text] [Related]
8. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.
Freedland SJ; Seligson DB; Liu AY; Pantuck AJ; Paik SH; Horvath S; Wieder JA; Zisman A; Nguyen D; Tso CL; Palotie AV; Belldegrun AS
Prostate; 2003 Apr; 55(1):71-80. PubMed ID: 12640663
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
10. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
Minner S; Jessen B; Stiedenroth L; Burandt E; Köllermann J; Mirlacher M; Erbersdobler A; Eichelberg C; Fisch M; Brümmendorf TH; Bokemeyer C; Simon R; Steuber T; Graefen M; Huland H; Sauter G; Schlomm T
Clin Cancer Res; 2010 Mar; 16(5):1553-60. PubMed ID: 20179235
[TBL] [Abstract][Full Text] [Related]
11. JunD mediates androgen-induced oxidative stress in androgen dependent LNCaP human prostate cancer cells.
Mehraein-Ghomi F; Lee E; Church DR; Thompson TA; Basu HS; Wilding G
Prostate; 2008 Jun; 68(9):924-34. PubMed ID: 18386285
[TBL] [Abstract][Full Text] [Related]
12. Expression of bone morphogenetic protein-7 (BMP-7) in human prostate.
Masuda H; Fukabori Y; Nakano K; Shimizu N; Yamanaka H
Prostate; 2004 Apr; 59(1):101-6. PubMed ID: 14991870
[TBL] [Abstract][Full Text] [Related]
13. Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma.
Zhigang Z; Wenlu S
Prostate; 2005 Dec; 65(4):299-305. PubMed ID: 16015594
[TBL] [Abstract][Full Text] [Related]
14. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
15. A novel human prostate-specific gene-1 (HPG-1): molecular cloning, sequencing, and its potential involvement in prostate carcinogenesis.
Herness EA; Naz RK
Cancer Res; 2003 Jan; 63(2):329-36. PubMed ID: 12543784
[TBL] [Abstract][Full Text] [Related]
16. Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival.
Daneshmand S; Quek ML; Lin E; Lee C; Cote RJ; Hawes D; Cai J; Groshen S; Lieskovsky G; Skinner DG; Lee AS; Pinski J
Hum Pathol; 2007 Oct; 38(10):1547-52. PubMed ID: 17640713
[TBL] [Abstract][Full Text] [Related]
17. Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells.
Grzmil M; Thelen P; Hemmerlein B; Schweyer S; Voigt S; Mury D; Burfeind P
Am J Pathol; 2003 Aug; 163(2):543-52. PubMed ID: 12875974
[TBL] [Abstract][Full Text] [Related]
18. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
19. Gene expression in the LNCaP human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo.
Chen Q; Watson JT; Marengo SR; Decker KS; Coleman I; Nelson PS; Sikes RA
Cancer Lett; 2006 Dec; 244(2):274-88. PubMed ID: 16500022
[TBL] [Abstract][Full Text] [Related]
20. Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer.
Yip PY; Kench JG; Rasiah KK; Benito RP; Lee CS; Stricker PD; Henshall SM; Sutherland RL; Horvath LG
Prostate; 2011 Nov; 71(15):1638-45. PubMed ID: 21432866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]